Acclarent, a maker of a device for sinus treatments, has raised $35 million in a third round of funding, VentureWire reports (sub required):

Acclarent, based in Menlo Park, Calif., was founded in June 2004 to develop a balloon sinuplasty device as a less invasive way to treat chronic sinusitis. The device is inserted through the nose via a guidewire into the targeted sinus. The balloon is then inflated, enlarging the sinus openings, allowing for normal drainage.

Meritech Capital Partners led the round, joined by Delphi Ventures and existing investors New Enterprise Associates, Versant Ventures, as well as individual investors.

VentureBeat

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member